CN105934256B - Pi3k-抑制剂的组合产品 - Google Patents

Pi3k-抑制剂的组合产品 Download PDF

Info

Publication number
CN105934256B
CN105934256B CN201480074721.5A CN201480074721A CN105934256B CN 105934256 B CN105934256 B CN 105934256B CN 201480074721 A CN201480074721 A CN 201480074721A CN 105934256 B CN105934256 B CN 105934256B
Authority
CN
China
Prior art keywords
dihydroimidazo
methoxy
quinazolin
amino
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480074721.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105934256A (zh
Inventor
刘宁姝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN105934256A publication Critical patent/CN105934256A/zh
Application granted granted Critical
Publication of CN105934256B publication Critical patent/CN105934256B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480074721.5A 2013-12-03 2014-11-28 Pi3k-抑制剂的组合产品 Expired - Fee Related CN105934256B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195485.1 2013-12-03
EP13195485 2013-12-03
PCT/EP2014/075886 WO2015082322A1 (en) 2013-12-03 2014-11-28 COMBINATION of PI3K-INHIBITORS

Publications (2)

Publication Number Publication Date
CN105934256A CN105934256A (zh) 2016-09-07
CN105934256B true CN105934256B (zh) 2019-12-27

Family

ID=49683606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480074721.5A Expired - Fee Related CN105934256B (zh) 2013-12-03 2014-11-28 Pi3k-抑制剂的组合产品

Country Status (6)

Country Link
US (1) US10117874B2 (enExample)
EP (1) EP3077002B1 (enExample)
JP (1) JP6499657B2 (enExample)
CN (1) CN105934256B (enExample)
CA (1) CA2932221C (enExample)
WO (1) WO2015082322A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
PE20151780A1 (es) 2013-04-08 2015-12-20 Bayer Pharma AG Uso de 2 - 3 dihidroimidazo[ 1,2- c] quinazolinas sustituidas
EP3077003A1 (en) 2013-12-03 2016-10-12 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
EP3426657B1 (en) 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
CN109729716B (zh) * 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
AU2018206453A1 (en) * 2017-01-05 2019-07-25 Mbc Pharma, Inc. Drug combination treatments using bone-targeting therapeutics for bone and bone-related disease
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336300A (zh) * 2005-12-16 2008-12-31 健泰科生物技术公司 神经胶质瘤的诊断、预后和治疗方法
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
EP1735013B1 (en) 2004-02-20 2012-02-08 Algeta ASA Alpha- and beta-emitting hydroxyapatite particles
GB201007353D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201007354D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
US9730943B2 (en) 2010-11-11 2017-08-15 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines
JP5940078B2 (ja) 2010-11-11 2016-06-29 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ アリールアミノアルコール−置換２，３−ジヒドロイミダゾ［１，２−ｃ］キノリン
DE102011079031A1 (de) 2011-07-12 2013-01-17 Algeta Asa Flüssigkeitsbehälter

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336300A (zh) * 2005-12-16 2008-12-31 健泰科生物技术公司 神经胶质瘤的诊断、预后和治疗方法
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Advanced prostate cancer—a case for adjuvant differentiation therapy;Jayant K. Rane et al;《NATURE REVIEWS UROLOGY》;20120814;第9卷;第595-602页 *
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer;Isabel Heidegger et al;《Journal of Steroid Biochemistry & Molecular Biology》;20131130;第138卷;第248-256页 *
Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases;Michel D. Wissing1 et al,;《Clin Cancer Res》;20130919;第19卷(第21期);第5822-5827页 *

Also Published As

Publication number Publication date
JP2017501983A (ja) 2017-01-19
US10117874B2 (en) 2018-11-06
US20160303136A1 (en) 2016-10-20
CN105934256A (zh) 2016-09-07
EP3077002B1 (en) 2020-04-22
JP6499657B2 (ja) 2019-04-10
CA2932221A1 (en) 2015-06-11
CA2932221C (en) 2022-02-22
EP3077002A1 (en) 2016-10-12
WO2015082322A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
CN105934256B (zh) Pi3k-抑制剂的组合产品
TWI689307B (zh) 經取代之2,3-二氫咪唑并[1,2-c]喹唑啉之用途
US11046699B2 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
CN107864625A (zh) 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品
JP2022177113A (ja) Ｐｉ３ｋ－阻害剤の組み合わせ
WO2016087490A1 (en) Combination of pi3k-inhibitors
WO2015082376A2 (en) Use of pi3k-inhibitors
US10124007B2 (en) Combination of PI3K-inhibitors
US20210187134A1 (en) Combination of pi3k-inhibitors and targeted thorium conjugates
US20220118123A1 (en) Combination of ar antagonists and targeted thorium conjugates
HK1228733A1 (en) Combination of p13k-inhibitors
WO2017157418A1 (en) Combination of mknk1-inhibitors
US11185549B2 (en) Combination of a PI3K-inhibitor with an androgen receptor antagonist
JP2018502863A (ja) 白血病の治療のための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用
TW201417816A (zh) Ａｋｔ抑制劑組合
WO2020164997A1 (en) Combination of pi3k-inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1228733

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1228733

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191227